Dupuytren's disease: a localised and accessible human fibrotic disorder

Dupuytren's disease: a localised and accessible human fibrotic disorder

We review the biology of Dupuytren's disease (DD), a common localised fibrotic disorder of the hand. The disease develops through a complex interplay of genetic and environmental factors, and epigenetic signalling. The early-stage disease nodules comprise a complex milieu of stromal and immune...

Descripció completa

Dades bibliogràfiques
Autors principals:	Layton, TB, Williams, L, Nanchahal, J
Format:	Journal article
Idioma:	English
Publicat:	Cell Press 2022

Ítems similars

Single cell analysis of the fibrotic landscape in Dupuytren's disease
per: Layton, T
Publicat: (2019)

Recent advances in the understanding of Dupuytren's disease
per: Nanchahal, J, et al.
Publicat: (2019)

Treatment for Dupuytren's disease
per: Nanchahal, J, et al.
Publicat: (2013)

A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: importance in human fibrotic disease
per: Layton, TB, et al.
Publicat: (2022)

Tonometry as an outcome measure for the treatment of Dupuytren’s disease.
per: Ball, C, et al.
Publicat: (2015)

Tonometry as an outcome measure for the treatment of Dupuytren’s disease.
per: Ball, C, et al.
Publicat: (2016)

Treatments for early-stage Dupuytren’s disease: an evidence-based approach
per: Nanchahal, J, et al.
Publicat: (2023)

A systematic review of non-surgical treatments for early Dupuytren’s disease
per: Ball, C, et al.
Publicat: (2015)

Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells
per: Nataly Puerta Cavanzo, et al.
Publicat: (2022-08-01)

Systematic review of non-surgical treatments for early Dupuytren’s disease
per: Ball, C, et al.
Publicat: (2016)

Predicting the outcome of surgery for the proximal interphalangeal joint in Dupuytren's disease.
per: Misra, A, et al.
Publicat: (2007)

Dupuytren’s disease
per: Richard Trèves
Publicat: (2011-09-01)

Dupuytren's disease
per: Rames Mattar Junior
Publicat: (2008-03-01)

Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture.
per: Verjee, L, et al.
Publicat: (2009)

What do we know about managing Dupuytren’s Disease cost-effectively?
per: Dritsaki, M, et al.
Publicat: (2018)

Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.
per: Ball, C, et al.
Publicat: (2013)

Method of treating a localized fibrotic disorder using an IL-33 antagonist
per: Jagdeep Nanchahal, et al.
Publicat: (2018)

What do we know about managing Dupuytren’s disease cost-effectively?
per: Melina Dritsaki, et al.
Publicat: (2018-01-01)

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)
per: Png, M, et al.
Publicat: (2019)

Paediatric Dupuytren's disease
per: Pradeoth Mukundan Korambayil, et al.
Publicat: (2011-09-01)

Isometric contraction of Dupuytren's myofibroblasts is inhibited by blocking intercellular junctions.
per: Verhoekx, J, et al.
Publicat: (2013)

Isometric contraction of dupuytren's myofibroblasts is inhibited by blocking intercellular junctions
per: Verhoekx, J, et al.
Publicat: (2013)

A genome-wide association meta-analysis implicates Hedgehog and Notch signaling in Dupuytren’s disease
per: Sophie A. Riesmeijer, et al.
Publicat: (2024-01-01)

Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.
per: Verjee, L, et al.
Publicat: (2013)

Unravelling the signalling pathways promoting fibrosis in dupuytren's disease reveals TNF as a therapeutic target
per: Verjee, L, et al.
Publicat: (2014)

Collagen VI as a driver and disease biomarker in human fibrosis
per: Williams, L, et al.
Publicat: (2021)

Wnt signaling and Dupuytren's disease.
per: Dolmans, G, et al.
Publicat: (2011)

The molecular genetics of dupuytren disease
per: Ng, M
Publicat: (2018)

Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.
per: Verjee, L, et al.
Publicat: (2010)

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 2; referees: 2 approved]
per: May Ee Png, et al.
Publicat: (2019-02-01)

Is Dupuytren’s disease really a “disease of the Vikings”?
per: Ng, M, et al.
Publicat: (2019)

Guillaume Dupuytren
per: Romina A Parquet
Publicat: (2013-01-01)

Sibling recurrence risk in Dupuytren's disease.
per: Capstick, R, et al.
Publicat: (2013)

Dupuytrens disease–where to from here?
per: David B McCombe
Publicat: (2019-03-01)

Epidemiological analysis of patients with Dupuytren's disease
per: Henrique Gonçalves Mansur, et al.

Surgical treatment results for dupuytren's disease
per: Serkan Aykut, et al.
Publicat: (2017-06-01)

The Rationale for Treating the Nodule in Dupuytren’s Disease
per: Lynn D. Ketchum, MD
Publicat: (2014-12-01)

Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300
per: Williams, LM, et al.
Publicat: (2020)

Enfermedad de Dupuytren
per: J. M. Arandes Renú
Publicat: (2010-11-01)

Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.
per: Helen B Forrester, et al.
Publicat: (2013-01-01)